帝人株式会社 2024年3月期業績予想の修正に関するお知らせ

This document informs about Teijin Limited's revision of its consolidated earnings forecast for the fiscal year ending March 2024. The revision is attributed to the impact of upfront payments for pharmaceuticals in the healthcare segment, demand softening in certain applications within the materials segment, inventory adjustments in the supply chain, and recurring equipment failures in the composite materials business. While the sales forecast remains unchanged at 1,030,000 million yen, operating profit has been revised down from 35,000 million yen to 18,000 million yen, ordinary profit from 31,000 million yen to 19,000 million yen, and net profit attributable to parent shareholders from 13,000 million yen to 8,000 million yen. There is no revision to the dividend forecast.